ArticleInfectious diseases of poverty2014
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.
Article in Infectious diseases of poverty, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment.Molecules (Basel, Switzerland) · 2017Pooled it
- Ebola virus disease in the modern era: pathogenesis, therapeutic advances, vaccine strategies, and global health preparedness.Infection · 2026Review
- Ebola virus disease: A persistent challenge in global health security.Open veterinary journal · 2026Review
- Characterizing changes in transcriptome and kinome responses in testicular cells during infection by Ebola virus.Npj viruses · 2024Article
- Convalescent-plasma-transfusion intelligent framework for rescuing COVID-19 patients across centralised/decentralised telemedicine hospitals based on AHP-group TOPSIS and matching component.Applied intelligence (Dordrecht, Netherlands) · 2021Article
- Convalescent Plasma Transfusion for the Treatment of COVID-19-Experience from Poland: A Multicenter Study.Journal of clinical medicine · 2020Article
- Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.Computer methods and programs in biomedicine · 2020Article
- Ebola virus: A global public health menace: A narrative review.Journal of family medicine and primary care · 2019Review
- Convalescent plasma: new evidence for an old therapeutic tool?Blood transfusion = Trasfusione del sangue · 2016Review
- Repurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic review.Systematic reviews · 2015Article
- Estimating the basic reproductive ratio for the Ebola outbreak in Liberia and Sierra Leone.Infectious diseases of poverty · 2015Article
- CombAlign: a code for generating a one-to-many sequence alignment from a set of pairwise structure-based sequence alignments.Source code for biology and medicine · 2015Article
- Possible FDA-approved drugs to treat Ebola virus infection.Infectious diseases of poverty · 2015Article
- Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.Current therapeutic research, clinical and experimentalArticle
- The Ebola Outbreak of 2014-2015: From Coordinated Multilateral Action to Effective Disease Containment, Vaccine Development, and Beyond.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of the human Zaire ebolavirus (EBOV) epidemic is spiraling out of control in West Africa. Human EBOV hemorrhagic fever has a case fatality rate of up to 90%. The EBOV is classified as a biosafety level 4 pathogen and is considered a category A agent of bioterrorism by Centers for Disease Control and Prevention, with no approved therapies and vaccines available for its treatment apart from supportive care. Although several promising therapeutic agents and vaccines against EBOV are undergoing the Phase I human trial, the current epidemic might be outpacing the speed at which drugs and vaccines can be produced. Like all viruses, the EBOV largely relies on host cell factors and physiological processes for its entry, replication, and egress. We have reviewed currently available therapeutic agents that have been shown to be effective in suppressing the proliferation of the EBOV in cell cultures or animal studies. Most of the therapeutic agents in this review are directed against non-mutable targets of the host, which is independent of viral mutation. These medications are approved by the Food and Drug Administration (FDA) for the treatment of other diseases. They are available and stockpileable for immediate use. They may also have a complementary role to those therapeutic agents under development that are directed against the mutable targets of the EBOV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.